Health Care & Life Sciences » Pharmaceuticals | Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
179.45 M
Public Float
149.32 M
Synergy Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$0.65
Market Cap
$414.14 M
Shares Outstanding
247.99 M
Public Float
247.16 M

Profile

Address
420 Lexington Avenue
New York New York 10170
United States
Employees -
Website http://www.synergypharma.com
Updated 09/14/2018
Synergy Pharmaceuticals, Inc. engages on the development and commercialization of novel gastrointestinal therapies. Its commercial product, plecanatide, is marketed under the trademark name TRULANCE, which seeks to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. The company was founded by Kunwar Shailubhai on November 15, 2005 and is headquartered in New York, NY.

Financials

View All

Gary S. Jacob
Executive Chairman
Troy Hamilton
Chief Executive Officer & Director